Feature Articles

As it seeks to become a top pharmaceutical company, Chugai places a priority on diversity, and in 2010 began working on a series of full-fledged diversity initiatives. In the five years since, what have we achieved, and what issues have become apparent? This feature offers a number of recent examples that describe the current state of diversity at Chugai.

Chugai has reorganized its in-house training system with the goal of developing internal audit personnel for ISO14001 (an international standard for environmental management systems) with global-level skills.

Chugai provides biopharmaceuticals, molecular targeted therapies, and other innovative pharmaceuticals to patients around the world. With new modes of action, they are highly effective, but their downside is that they may cause unforeseen adverse reactions or other problems. For that reason, Chugai established the Drug Safety Division, which is staffed by a team of safety experts and reports directly to top management, to create a comprehensive pharmacovigilance system that helps patients to correctly use Chugai products. With these measures, Chugai aims to promote more appropriate use of its medicines and build further trust among patients and healthcare providers.

Human resource management that promotes diversity of gender, nationality and age will help Chugai become a top Japanese pharmaceutical company.

Chugai's program of donating specially-equipped welfare vehicles to groups throughout Japan that provide home welfare services to the elderly and disabled

Individual Chugai Group employees involved in areas from discovery research to development, production engineering, and information provision talk about their daily work.

Chugai is undertaking initiatives to counter global warming by reducing CO2 emissions from energy consumption and working to prevent the release of halogenated hydrocarbons.

Breast cancer is the most common form of cancer in women, with about 40,000 cases diagnosed each year in Japan. Chugai invited two people closely involved in this field, Dr. Seigo Nakamura and Ms. Misako Togashi, to talk with Akio Tanaka, head of Chugai's Oncology Unit, about current and future issues in cancer treatment and Chugai's role in realizing patient-centered cancer care.
Moderator: Fumihisa Oshimi, Director, Link Investor Relations Inc.

Launches of new products, the introduction of additional indications and a growing product lineup have made Chugai the number-one provider of anti-cancer medicines in Japan. With this success come higher expectations from society. To become a true leader in cancer treatment, we have begun various initiatives to develop CHUGAI ONCOLOGY into the strongest, most trusted brand and to make Chugai synonymous with oncology.